HOME >> BIOLOGY >> NEWS
Weill Cornell pharmacologist receives prestigious NIH MERIT Award

$2.5 million grant supports research into potential pharmaceutical targets for treating vascular complications of diabetes

NEW YORK (May 21, 2007) -- A leading authority and pioneer in the pharmacology of the signaling molecule nitric oxide (NO), Weill Cornell Medical College scientist Dr. Steven S. Gross has been selected by the National Heart, Lung, and Blood Institute (NHLBI) to receive a 2007 National Institutes of Health (NIH) Method to Extend Research in Time (MERIT) Award, representing the fourth year the College has been selected for the prestigious honor.

This year's $2.5 million five-year research grant will provide long-term support for research aimed at furthering understanding of the NO-related trigger for vascular complications of diabetes and developing novel pharmaceutical approaches for ameliorating the condition.

Dr. Gross is professor of pharmacology, director of the mass spectrometry core facility and principal investigator on an NIH grant that supports the training of Ph.D. candidates in the Graduate School Program in Pharmacology at Weill Cornell Medical College.

"We are extremely grateful for the NIH's continued support for our translational research efforts," says Dr. Antonio M. Gotto Jr., the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College. "Dr. Gross is highly deserving of this honor. His research has uncovered a wealth of information about the important role of nitric oxide in the body. This work, which has laid the groundwork for treatments of numerous disease conditions that have been attributed to nitric oxide excess or insufficiency, is currently focused on new approaches for one of the most painful complications of diabetes."

Beginning in the late 1980s, Dr. Gross and colleagues made several key discoveries about nitric oxide. Working with Dr. Roberto Levi and colleagues at Weill Cornell, Dr. Gross was a member of the first group to administer a selective inh
'"/>

Contact: Andrew Klein
ank2017@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
21-May-2007


Page: 1 2 3 4

Related biology news :

1. Weill Cornell team identifies potential new cancer drug target
2. Stem cell research at Weill Cornell, The Rockefeller University, and Sloan-Kettering
3. Weill Cornell team develops fast-acting anthrax vaccine
4. Cornell scientists link E. coli bacteria to Crohns disease
5. Methodist, University of Houston, Cornell combine biomedical imaging expertise
6. Cornell lab confirms deadly fish virus spreading to new species
7. NSF awards $3.3 million grant to Cornell to bolster the percentage of women faculty members
8. Cornell researchers find serious fish virus in Northeast for first time
9. Cornell finds natural selection in humans
10. Northeast Sun Grant Institute at Cornell spurs green revolution
11. Cornell graduate student named 2005 AIBS Emerging Public Policy Leader

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
(Date:3/30/2017)... ANGELES , March 30, 2017  On April ... Hack the Genome hackathon at Microsoft,s ... exciting two-day competition will focus on developing health and ... Hack the Genome is the ... been tremendous. The world,s largest companies in the genomics, ...
(Date:3/28/2017)... PUNE, India , March 28, 2017 ... (Analog, IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), ... Maintenance), Vertical, and Region - Global Forecast to 2022", ... 30.37 Billion in 2016 and is projected to reach ... 15.4% between 2017 and 2022. The base year considered ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity of ... performing systematic gain-of-function studies. , This complement to loss-of-function studies, such as ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. 11, ... Research, London (ICR) and University of ... SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma (MM), ... nine . The University of Leeds ... funded by Myeloma UK, and ICR will perform the testing ...
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... innovation and business process optimization firm for the life sciences and healthcare industries, ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile ...
Breaking Biology Technology:
Cached News: